HISTORICAL FACTS: New england journal of medicine - The Untold Story

Blood Sugar Fluctuations Without Diabetes Are Still Quietly Damaging Your Brain

The spike-crash cycle your report calls normalA fasting glucose of 95 mg/dL looks fine on paper. But if that number climbs to 160 after a meal and drops to 72 two hours later, the brain is absorbing a punishment the report never records. Each spike triggers a surge of insulin.…

Times Life · Aug 20

‘They’re all corrupt!’: RFK Jr. threatens to pull government scientists from top medical journals

Losing scientists one day at a time.

We Got This Covered · May 28, 2025

RFK Jr threatens ban on federal scientists publishing in top journals

US health secretary calls leading medical journals such as Lancet ‘corrupt’ and pushes to create state-run alternatives

The Guardian - US · May 28, 2025

Commentary: We shouldn’t get caught up in the hype over new Alzheimer’s drug

This month, the Food and Drug Administration approved a new drug, lecanemab, for the treatment of Alzheimer’s disease. The drug, sold under the brand name Leqembi, was developed by Japanese pharmaceutical company Eisai and will be marketed commercially in partnership with American pharmaceutical company Biogen. Biogen, notably, is the maker…

Chicago Tribune · Jan 30, 2023

Did Damar Hamlin experience commotio cordis? What to know about the rare phenomenon

It involves the impact of a specific force to the chest at a specific moment in the cardiac cycle. One cardiologist told NPR that what happened to Hamlin was likely "a perfect storm of events."

WEKU · Jan 3, 2023

Lecanemab: Experimental drug is a ray of hope for Alzheimer's disease

On Nov. 30, Eisai and Biogen announced the results of their latest phase 3 clinical trial in Alzheimer’s disease. The verdict: an 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The study…

The Conversation · Dec 21, 2022

Health: New Treatment Discovered For Rare Eye Disease May Prevent Blindness

Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life, according to a study recently published in the New England Journal of Medicine. Read on for details:

Dynamite News · Dec 19, 2022

A new drug appears to slow Alzheimer’s. Here’s what to know

An experimental drug appears to slow cognitive decline in people with early onset Alzheimer’s.

Tribune News Service · Dec 7, 2022

For some COVID patients, 'Paxlovid rebound' has nothing to do with Paxlovid

This is a story about a COVID-19 medication, a nasty trick the coronavirus sometimes plays on its victims, and how the two became a pandemic couple called "Paxlovid rebound."

Los Angeles Times · Nov 15, 2022

Faye Flam: Better cancer screenings are coming. Can we afford them?

Patients and their doctors count on cancer screening tests to save lives, and yet a number of large, controlled studies are showing disappointing results for mammography and other mass screening tests. This month, the New England Journal of Medicine published a controversial study that cast doubt on the widely accepted…

Tribune News Service · Oct 26, 2022